G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
Curtis Lachowiez,Gautam Borthakur,Sanam Loghavi,Zhihong Zeng,Tapan M. Kadia,Lucia Masarova,Koichi Takahashi,George Dono Tippett,Samantha Smith,Jacqueline S. Garcia,Prithviraj Bose,Elias Jabbour,Farhad Ravandi,Naval Daver,Guillermo Garcia-Manero,Bilyana Stoilova,Paresh Vyas,Hagop M. Kantarjian,Marina Konopleva,Courtney D. DiNardo +19 more
TL;DR: This data indicates that the presence of IDH1 mutations in myeloid malignancies promotes leukemogenesis through production of the oncometabolite 2-hydroxyglutarate resul...
Journal ArticleDOI
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
Aref Al-Kali,Aref Al-Kali,Alfonso Quintás-Cardama,Raja Luthra,Carlos E. Bueso-Ramos,Sherry Pierce,Tapan M. Kadia,Gautam Borthakur,Zeev Estrov,Elias Jabbour,Stefan Faderl,Farhad Ravandi,J. E. Cortes,Ayalew Tefferi,Hagop M. Kantarjian,Guillermo Garcia-Manero +15 more
TL;DR: RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome, and no differences were observed between both groups regarding the risk of AML transformation and overall survival.
Journal ArticleDOI
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
Aziz Nazha,Mikkael A. Sekeres,Guillermo Garcia-Manero,John Barnard,Najla Al Ali,Gail J. Roboz,David P. Steensma,Amy E. DeZern,Cassie Zimmerman,Elias Jabbour,Katrina Zell,Alan F. List,Hagop M. Kantarjian,Jaroslaw P. Maciejewski,Rami S. Komrokji +14 more
TL;DR: Patients treated with HMAs who achieves CR after a SD status had longer survival with continuous treatment after 6 months, and patients with SD who subsequently achieved CR had superior OS compared to patients who remained with SD.
Journal Article
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Francis J. Giles,Jorge E. Cortes,Deborah A. Thomas,Guillermo Garcia-Manero,Stephan Faderl,Sima Jeha,Robert L. De Jager,Hagop M. Kantarjian +7 more
TL;DR: DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies and was linear and well fit by a two-compartment model.
Journal ArticleDOI
Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Deborah A. Thomas,Hagop M. Kantarjian,Jorge E. Cortes,Stefan Faderl,Francis J. Giles,Guillermo Garcia-Manero,William G. Wierda,Alessandra Ferrajoli,Farhad Ravandi-Kashani,Srdan Verstovsek,Michael Andreeff,Laurie Letvak,Laurie Letvak,Dan Jones,Richard E. Champlin,Susan O'Brien +15 more
TL;DR: Although complete remission (CR) rates with the hyper-CVAD regimen in de novo adult Ph-ALL were 90% or better, remissions were brief with median CR duration of 16 months (mos) and deaths in CR occurred in 12 pts (5 related to infections, 4 related to complications of allogeneic SCT, 1 pancreatitis, 1 intracranial hemorrhage, 1 unknown).